Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
The Future Is Now: Matthias Alder Of Gain Therapeutics On How Their Technological Innovations Will Shake Up The Tech Scene
The Authority Magazine
Related Posts
Post navigation
Previous Post
The Future Is Now: Matthias Alder Of Gain Therapeutics On How Their Technological Innovations Will Shake Up The Tech Scene
Next Post
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
Latest Articles
Clear Filters
May 12, 2023
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Read More
March 15, 2022
Krabbe Translational Research Network Meeting
Read More
March 5, 2024
Phase 1 trial of therapy for GBA1 Parkinson’s advances in dosing
Read More
Close